Pluristem (PSTI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pluristem (PSTI) has a cash flow conversion efficiency ratio of -0.235x as of March 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-9.42 Million ≈ $-25.26K USD) by net assets (ILA40.14 Million ≈ $107.62K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pluristem - Cash Flow Conversion Efficiency Trend (2014–2021)
This chart illustrates how Pluristem's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Pluristem total liabilities for a breakdown of total debt and financial obligations.
Pluristem Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pluristem ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Taiwan Alpha Electronic Co Ltd
TWO:6204
|
0.009x |
|
Al-Salam Real Estate Investment Trust
KLSE:5269
|
0.068x |
|
Hunya Foods Co Ltd
TW:1236
|
0.036x |
|
Salcon Engineering Berhad
KLSE:8567
|
0.077x |
|
Thitikorn Public Company Limited
BK:TK
|
0.001x |
|
Fine Blanking & Tool Co Ltd
TWO:4535
|
0.036x |
|
Dawonsys Co.Ltd
KQ:068240
|
0.103x |
|
Song Shang Electronics Co Ltd
TWO:6156
|
-0.075x |
Annual Cash Flow Conversion Efficiency for Pluristem (2014–2021)
The table below shows the annual cash flow conversion efficiency of Pluristem from 2014 to 2021. For the full company profile with market capitalisation and key ratios, see PSTI company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2021-06-30 | ILA57.15 Million ≈ $153.22K |
ILA-30.91 Million ≈ $-82.87K |
-0.541x | -15.07% |
| 2020-06-30 | ILA56.10 Million ≈ $150.40K |
ILA-26.37 Million ≈ $-70.69K |
-0.470x | +65.18% |
| 2019-06-30 | ILA21.82 Million ≈ $58.50K |
ILA-29.45 Million ≈ $-78.96K |
-1.350x | -79.97% |
| 2018-06-30 | ILA28.51 Million ≈ $76.43K |
ILA-21.38 Million ≈ $-57.32K |
-0.750x | -4.98% |
| 2017-06-30 | ILA30.25 Million ≈ $81.10K |
ILA-21.61 Million ≈ $-57.94K |
-0.714x | -47.17% |
| 2016-06-30 | ILA38.16 Million ≈ $102.29K |
ILA-18.52 Million ≈ $-49.66K |
-0.485x | -36.98% |
| 2015-06-30 | ILA58.14 Million ≈ $155.88K |
ILA-20.61 Million ≈ $-55.24K |
-0.354x | -15.14% |
| 2014-06-30 | ILA62.12 Million ≈ $166.55K |
ILA-19.12 Million ≈ $-51.26K |
-0.308x | -- |
About Pluristem
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase I… Read more